Commercial launch of DRDO's anti-cancer drug likely soon

Technology transferred to a Hyderabad-based laboratory: scientist

November 15, 2010 11:20 pm | Updated 11:23 pm IST - CHENNAI:

LAB TO LAYMAN: S.C. Chetal, Director, Research Engineering Group, IGCAR releasing a book  by handing over a copy to V.R. Venkatachalam, Chancellor, Sri Ramachandra University, at the inaguration of the International Conference on Radio Biology in Chennai on Monday. M. Natarajan (second from right), Former Scientific Advisor to Defence Minister and Secreatry, DRDO, and S.P. Thyagarajan, Pro-Chancellor are in the picture. Photo: K. Pichumani

LAB TO LAYMAN: S.C. Chetal, Director, Research Engineering Group, IGCAR releasing a book by handing over a copy to V.R. Venkatachalam, Chancellor, Sri Ramachandra University, at the inaguration of the International Conference on Radio Biology in Chennai on Monday. M. Natarajan (second from right), Former Scientific Advisor to Defence Minister and Secreatry, DRDO, and S.P. Thyagarajan, Pro-Chancellor are in the picture. Photo: K. Pichumani

A promising anti-cancer drug developed by the Defence Research and Development Organisation (DRDO) is likely to be commercially launched soon, a senior DRDO scientist said on Monday.

Interacting with reporters on the sidelines of an international conference on radiation biology hosted by Sri Ramachandra University (SRU) and the Indian Society for Radiation Biology (ISRB), B.S. Dwarakanath, scientist with DRDO said the 2-Deoxy-D-Glucose (2-DG) drug had cleared three clinical trials (Phase I, II and III) and also been approved by the Drugs Controller General of India.

“The drug is now in an advanced stage of evaluation by a panel of the Indian Council of Medical Research for investigational new drugs and is likely to be cleared for market launch soon,” Dr. Dwarakanath said.

The technology has already been transferred to a Hyderabad-based laboratory.

The 2-DG holds out immense hope as an adjuvant compound, or an agent to be applied in combination with chemotherapy and radiation in the treatment of cancers, Dr. Dwarakanath said. The drug, similar in molecular structure to glucose, acts by altering the glucose mechanism of the body and denying sustenance to cancer cells that voraciously feed on glucose than oxygen.

Earlier, inaugurating the conference, M. Natarajan, former scientific adviser to the Defence Minister and DRDO secretary, called for more research on developing early bio-markers in the evaluation and treatment of cancer. Stressing the need to develop innovative technologies for diagnosis through radio-biology research, Dr. Natarajan also highlighted the importance of evolving a base of trained researchers.

“We need to motivate young medical and other stream graduates as well as post graduates to undertake quality research,” he said.

In his key-note address, Mark Melanson, Director, armed Forces Radiobiology Research Institute, U.S., underlined the importance of global collaboration in maximising the beneficial uses of radiation while eliminating its harmful effects.

He pointed out that radiation was one of the most-studied and best understood of all human health hazards due to the century-old research efforts of the international scientific community.

P.K. Goyal, ISRB president, said one of the goals of the three-day conference was to appeal for a global effort from cancer centres to take the latest developments of radiation biology and oncology to the common man.

Mansoor M. Ahmed, event chairman, said cancer treatment was heading into an exciting era with discovery of important elements and with the spotlight turning to cancer-initiating cells.

S.P. Thyagarajan, SRU Pro-Chancellor (Research), said recent advances in radiation biology had led to newer cancer treatment strategies that held out possibilities for improving quality of life and minimising side-effects.

S.C. Chetal, Director, Research Engineering Group, IGCAR, Kalpakkam, said most beneficial spinoffs from radiation science had been in the field of nuclear medicine.

SRU Chancellor V.R. Venkataachalam, S. Rangaswami, Vice-Chancellor and K.V. Somasundaram, Dean of Faculties participated.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.